biodefense

(redirected from biodefence)
Also found in: Dictionary, Thesaurus.

biodefense

(bī″ō-dĕ-fĕns′) [″ + ″]
National or international efforts to prevent the spread of biologically destructive agents, esp. when they are used in terrorism or warfare.
Mentioned in ?
References in periodicals archive ?
In other words, the biodefence research in Kenema was conducted in a high-risk, largely unprotected environment.
Key opportunities exist in molecular reagent kits production and rapid biodefence tests for nerve agents and other biothreat agents.
We entered several government contracts to develop new biodefence products and we expanded our distribution agreements.
Addressing the future of biodefence and the necessary response from the legal community, Sutton highlights the legal issues surrounding the First Amendment to the United States Constitution (84) and restrictions on biological weapons information, (85) laboratory security, (86) and vaccines and immunities.
The projects include Biodefence designed to develop a completely new mechanism of rapid immunisation against bio-terrorist weapons, using transformed GRAS (Generally Regarded As Safe) organisms.
3M CONTRACT TO PSIOXUS THERAPEUTICS TO DEVELOP BIODEFENCE VACCINE ADJUVANTS
Prior information notice without call for competition: Preparing a collection of standards biologically significant toxins, with the support of the european network of laboratories biological protection (european biodefence laboratory network).
THE Pentagon has admitted a high-security biodefence facility mistakenly sent live anthrax samples to laboratories around the world.
Biodefence company PharmAthene (NYSE MKT:PIP) said on Thursday that it has met its obligations of a fixed price, indefinite delivery, indefinite quantity (IDIQ) contract for its anthrax anti-toxin, Valortim.
The transaction will boost Emergent's biodefence portfolio, the buyer's CEO, Daniel Abdun-Nabi, said in a statement on 11 December when the deal was announced, adding that the pro forma combined revenue of the companies would top USD430m.
25 November 2010 - US biodefence company PharmAthene Inc (AMEX:PIP) said on Wednesday the underwriter of its previously announced stock offer has taken full advantage of the over-allotment option for net proceeds of USD2.
The capital injection will be used to fulfil Bavarian Nordic's strategy within biodefence and cancer, focusing on the production of smallpox vaccine Imvamune and on the clinical development of therapeutic vaccine candidate Prostvac.